Navigation Links
ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers
Date:9/8/2011

IRVINE, Calif., Sept. 8, 2011 /PRNewswire/ -- ChromaDex® Corp. (OTCBB: CDXC) today announced that the University of California, Irvine has granted ChromaDex® the exclusive rights to a joint patent application filed by ChromaDex® and the university for the method of inducing UDP-glucuronosyltransferase (UGT) activity using pTeroPure®, ChromaDex®'s ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits. UGT is an enzyme responsible for the process of glucuronidation, which changes unwanted compounds in to a more water-soluble version, thus allowing for easier elimination from the body. It is known that UGTs prevent melanoma invasiveness by eliminating toxic compounds and are subsequently lost during melanoma progression.  

(Logo:  http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

With more than 3.5 million skin cancers diagnosed in more than two million people annually,(1) data shows that there has been at least a 300 percent increase in skin cancer incidence since 1994.(2) Researchers believe that pTeroPure® may show promise for the regression of precancerous diseases such as actinic keratoses (AK) and other changes that are associated with photodamage of the skin. AKs are the earliest identifiable lesions that can eventually develop into skin cancer. These lesions are diagnosed in 14 percent of all visits to dermatologists, following only acne and dermatitis in frequency according to the American Academy of Dermatology.

The pterostilbene-based pTeroPure® may also be used to suppress or prevent progression of these precancerous diseases to non-melanoma skin cancer (NMSC). In prior studies, pterostilbene has been shown to inhibit melanoma cell growth, although the mechanism of action is still being determined.(3)

"As we continue to build on our st
'/>"/>

SOURCE ChromaDex Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
2. Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity
3. Alzheimers Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
4. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
5. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
6. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
7. QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer
8. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
9. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
10. Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
11. Porter Novelli Named Agency of Record for Prix Galien USA Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... SUNNYVALE, Calif. , July 6, 2015   ... will report financial results for its 2015 second quarter ... after the close of the market. The ... Pacific Time on Thursday, July 23, 2015, to discuss ... Cepheid,s website at http://ir.cepheid.com at least 15 ...
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. , ... AGN ), a leading global pharmaceutical company, and Oculeve, ... treatments for dry eye disease, today announced that they ... acquire Oculeve in an all-cash transaction.  Under the terms ... $125 million upfront payment and commercialization milestone payments related ...
(Date:7/6/2015)... July 6, 2015 Akcea Therapeutics, a ... ISIS ), announced today that the U.S. Food ... to volanesorsen (ISIS-APOCIII Rx ) for the treatment ... is a rare genetic disease characterized by extremely ... a Phase 2 study published in the NEJM ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
... 2012  Atlanta-based Acella Pharmaceuticals, LLC, announces the addition ... and Marketing of their commercial team. Tom will ... Acella,s product line.    Tom is ... bringing more than 11 years of industry experience, ...
... 2012   Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... 31, 2012 before market open on Tuesday May 8, 2012. ... webcast at 9:00 am Eastern Time (6:00 am Pacific Time) ... Domestic callers: 1 (866) 543-6411 International callers: +1 (617) 213-8900 ...
Cached Medicine Technology:
(Date:7/6/2015)... ... July 06, 2015 , ... Dr. Lawrence Green is ... area patients. Kybella is a non-surgical method to dissolve fat cells and ... moderate to severe fat deposits under the chin, commonly known as a double chin. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Promero, a leading cloud ... Software Unified IP contact center solution hosted by Promero. Randstad Technologies,a leading ... its future call center platform. , Promero will implement and manage the ...
(Date:7/6/2015)... Newport News, VA (PRWEB) , ... July 06, ... ... announced today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® ... Bon Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an ...
(Date:7/6/2015)... ... 06, 2015 , ... Diabetes affects many of us and the Glycemic Load ... diabetes, the majority of which are Type 2. However, eight million do not know ... three, have prediabetes (abnormally high blood sugar levels). Without reductions in blood sugar levels ...
(Date:7/6/2015)... Akron, OH (PRWEB) , ... July 06, 2015 , ... ... Home Health and Hospice received the Music & Memory Certification for hospice patients ... bringing the power of music not only to patients but also to their families ...
Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4
... With sights set on advanced science degrees and careers ... now have the highest honor they can garner for ... Eastham, a junior chemistry major, and Thomas Markovich, a ... Barry M. Goldwater Scholars for the 2011-2012 academic year. ...
... 6, 2011 Researchers at The Scripps Research Institute have found ... to pour in and activate an immune response. This process can ... it fallssuch as when immune cells are "called" from the body,s ... The study, recently published online ahead of print by Nature ...
... international panel of experts from The Heart Rhythm Society ... recommendations for all health care professionals about cardiovascular genetic ... Sessions. Silvia G. Priori, MD, PhD, a ... director of the Cardiovascular Genetics Program at NYU Langone ...
... National Academies Keck Futures Initiative announced today the recipients ... to support interdisciplinary research on imaging science. The ... such research, which was the subject of the eighth ... "We received far more high-quality proposals than funds available," ...
... A study published in the June 2011 issue of ... the association between patientphysician gender concordance and weight-related counseling ... and Johns Hopkins University found that obese male patients ... counseling than obese women seeing a female physician. ...
... Reporter , THURSDAY, May 5 (HealthDay News) -- You stand ... while you,re in an exercise facility than if you,re in ... Overall, 50 percent of cardiac arrest victims survived ... sort of exercise was happening, whereas only 36 percent of ...
Cached Medicine News:Health News:2 students named Goldwater Scholars, 2 receive honorable mention 2Health News:2 students named Goldwater Scholars, 2 receive honorable mention 3Health News:Scripps Research scientists show how shifts in temperature prime immune response 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 3Health News:New guidelines for cardiovascular genetic testing 2Health News:Keck Futures Initiative awards $1 million for 13 research projects 2Health News:Keck Futures Initiative awards $1 million for 13 research projects 3Health News:Keck Futures Initiative awards $1 million for 13 research projects 4Health News:Keck Futures Initiative awards $1 million for 13 research projects 5Health News:Weight-loss counseling most prevalent between male physicians and obese men 2Health News:Cardiac Arrest Less Deadly in Exercise Facilities, Study Finds 2Health News:Cardiac Arrest Less Deadly in Exercise Facilities, Study Finds 3
Microforceps: Claes ILM Forceps...
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps with "nail-like" end-gripping platforms; for precise grasping and improved visualization of thin membranes in the macular region....
Microforceps : Eckardt Endgripping Forceps...
Medicine Products: